HGF and acute myeloid leukemia: Similarly, nearly 50% of examined AML specimens exhibit aberrant activation of HGF/MET/FGFR signaling (Kentsis et al., 2012) and are being currently targeted therapeutically in the ongoing clinical trial of combined MET and FGFR inhibitors in patients with relapsed or refractory AML (ClinicalTrials.gov Identifier NCT03125239).